Novo Nordisk A/S (NYSE:NVO) Receives $65.56 Consensus Target Price from Analysts

Shares of Novo Nordisk A/S (NYSE:NVO) have received a consensus rating of “Hold” from the twenty-three ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, seventeen have assigned a hold rating and five have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $65.5625.

NVO has been the subject of a number of research reports. The Goldman Sachs Group reiterated a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Kepler Capital Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a research note on Tuesday, March 3rd. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Finally, Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, May 12th.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $43.20 on Wednesday. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $74.38. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The stock has a market cap of $192.89 billion, a P/E ratio of 10.14, a price-to-earnings-growth ratio of 3.86 and a beta of 0.78. The firm’s fifty day moving average price is $42.92 and its 200-day moving average price is $45.83.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion for the quarter. On average, equities research analysts expect that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Novo Nordisk A/S

Several institutional investors have recently bought and sold shares of the stock. Western Wealth Management LLC increased its stake in Novo Nordisk A/S by 89.9% in the 1st quarter. Western Wealth Management LLC now owns 16,271 shares of the company’s stock worth $598,000 after purchasing an additional 7,703 shares during the period. Shariaportfolio Inc. purchased a new stake in shares of Novo Nordisk A/S during the first quarter valued at approximately $1,146,000. LFG Wealth Partners LLC bought a new position in shares of Novo Nordisk A/S in the first quarter worth approximately $1,071,000. Rathbones Group PLC grew its holdings in shares of Novo Nordisk A/S by 12.0% in the first quarter. Rathbones Group PLC now owns 81,882 shares of the company’s stock worth $3,009,000 after purchasing an additional 8,744 shares during the last quarter. Finally, Parallel Advisors LLC increased its stake in shares of Novo Nordisk A/S by 27.8% in the first quarter. Parallel Advisors LLC now owns 55,856 shares of the company’s stock worth $2,053,000 after buying an additional 12,138 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.